Pre-clinical studies utilizing anti-mesothelin CAR-T cells, BiTEs, and anetumab ravtansine against mesothelin-expressing AML exhibit tumor-specific killing of leukemia cells, and the ability to reduce leukemic burden in vivo. Here, MSLN is linked to leukemia.